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I have known Peter since our early post-
military days in the 1960s, and we have 
remained very close friends ever since. When 
he applied for the post of Professor in South 
Africa, I was very pleased indeed to support 
him. Later, in 1988, he would successfully 
propose me for Honorary Fellowship of the 
Royal Society of South Africa.
However, very few people know of a certain 
incident from our distant past, one which has 
cemented our ties. Peter once saved my life, 
and in a most incredible way. I had been 
lecturing in Pondicherry in India and had 
been housed in a local ‘hotel’. But what a 
hotel! I was the only resident, there was no 
food and the manager, I discovered, dressed 
each evening as a woman and cycled into the 
village, leaving me the sole, unfed occupant 
of the lonely hotel. I developed a severe 
intestinal infection, the worst I had ever had. 
After 3 days I could no longer get out of bed; 
I was so weak and ill that I began to write 
my will. And on the fourth or fifth day I was 
awoken suddenly by banging on the bedroom 
door. It was Peter, who said he had heard of 
‘a foreigner in the village’. He more-or-less 
carried me to a taxi he had ordered, but when 
the young taxi driver learned that we wanted 
to travel to the British Consulate in Madras, 
he refused to take us. So Peter, and this is 
typical, said, ‘If I buy your taxi, will you take 
us?’ The young lad was astonished, and then 
delighted, to accept Peter’s offer, and so for 
about £50 Peter was the proud owner of the 
taxi, with chauffeur. After the journey, which 
must have been about 3 hours (I wasn’t 
aware of my surroundings at this point), we 
reached the British Consulate in Madras, 
whereupon Peter told the incredulous driver 
that he could keep his taxi. The young 
man no doubt left promptly, before these 
mad Englishmen changed their minds. The 
consulate immediately arranged for me to be 
flown home, and in Edinburgh I was treated 
with intravenous fluids and appropriate 
therapy. It turned out to be giardiasis (a 
protozoan infection), and within a week or 
so I fully recovered – but had lost two stone 
in weight. I never forgot Peter’s miraculous 
intervention, but never found out what on 
earth Peter was doing in Pondicherry! So 
Peter and I do have a bond for life.
In certain autosomal recessive disorders, 
there is suggestive evidence that heterozygous 
carriers may have some selective advantage 
over normal homozygotes. These include, for 
example, cystic fibrosis, Tay-Sachs disease 
and phenylketonuria. The best example so far, 
however, is that of significant heterozygous 
advantage in sickle-cell anaemia with 
increased resistance to falciparum malaria.[1] 
How a possible heterozygous advantage can 
be calculated has been detailed.[2]
More recently, the possibility of 
heterozygous advantage has been suggested 
in the case of a rare autosomal recessive 
form of congenital muscular dystrophy 
(MDC1D).[3] This disorder is caused by the 
mutation LARGE, in the gene locus at 22q12, 
which results in reduced glycosylation of 
α-dystroglycan, a protein located outside the 
muscle basement membrane (basal lamina) 
(Fig. 1).[4]
The extracellular protein α-dystroglycan 
is known to bind to various extracellular 
proteins (perlecan, agrin and laminins).[5] 
But most importantly, from the present point 
of view, α-dystroglycan provides a receptor 
for various pathogenic viruses, and this 
depends on effective glycosylation. There 
have been several recent reports detailing 
this molecular mechanism.[6-9] The defective 
and reduced glycosylation in MDC1D might 
therefore be expected to affect its function 
as a receptor for several viruses including 
Lassa fever and other arenaviruses. [10] In 
fact, glycosylation defects in fibroblasts 
are associated with resistance to murine 
leukaemia virus.[11]
Those disorders that could be relevant in the 
present context include many haemorrhagic 
viral diseases in Central Africa, South America 
and India, which have been described in 
detail by Garrett[12] and Karlen.[13]
These haemorrhagic diseases all present 
with internal bleeding, shock and the 
majority of patients succumb, though a few 
do survive. These diseases include Ebola 
fever, of which there has recently been 
an outbreak in West Africa. The question 
therefore is: could heterozygotes for 
α-dystroglycan LARGE mutations be in any 
way resistant to these diseases? Could this 
be tested for by determining heterozygosity 
in those who succumb to the disease and 
those who survive?
Such studies would not have to be confined 
to one disorder but to any of the haemorrhagic 
disorders. Furthermore, screening for any 
other defects in α-dystroglycan could be 
revealing even if unrelated to congenital 
muscular dystrophy, which is presumably 
rare in such populations anyway. 
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Fig. 1. Simplified diagrammatic representation of 
the relationship of α- and β-dystroglycans in the 
skeletal muscle membrane.
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